$10m Market cap in a $1b Market place? We're head up, way up folks.
People on the sidelines watching, and those ignorant enough to short are about to learn a painful lesson. Bristow (the CEO) is a world renowned Cardiologist specializing in Atrial Fibrillation. The market potential for a targeted beta blocker here is north of a billion dollars, consider the aging baby boomers. A company like this should be trading with a market cap of $130-200m, that would translate to at least $8.45/share target price. The market will normalize the price quickly, or someone like Merck will step in and buy the company. It's simple math at this point.